Perioptias offers a structured approach to business building and commercialisation, with results-driven outcomes tailored for your specific needs
Our partners are experienced at identifying and developing opportunities to grow your businesses.
Our consulting work, spanning business cases to gateway reviews, provided guidance to more than £1.8 bn (AU$3.3bn) of government investments, of which approximately 31% of the value was in health projects.
In the private sector we supported the growth of more than 80 high technology companies to receive more than £50 million in private equity funding
Perioptias’ vision is “to create a world-leading network of care organisations for the treatment of chronic and age-related diseases”.
Our organisation’s mission for the next five years is to build a world leading consulting and research group, formed through partnerships, and through our combined effort, make a major contribution to improved health outcomes. We will gather, invest in and share the best and latest services and technology to make life more comfortable for all people, and in particular chronically ill and retired people.
The initial objectives of Perioptias are to identify opportunities to influence the direction of healthcare through high level consultancies. In addition we will identify and support commercialisation opportunities to bring new services and technologies to the market.
Perioptias offers a unique combination of health care services in Australia as well as global experience in business strategy, new business development and close relationships with both Australian Federal and State Governments from senior public servants to Departmental Ministers.
Our principals have a strong healthcare focus, having served multinational and regional health corporate leaders in strategy, marketing and board-level roles.
Dr. Grace Lai through Periop Partners offers healthcare services including a particular focus on aged care operators, hospitals and surgical clinics and multi- disciplinary and Allied health Clinics. Grace is a highly qualified medical doctor, as well as holding qualifications in Business and Information Technology. She is closely networked with a range of service providers and colleagues, with extensive connections to China and South East Asia.
Dr. Ian Smart who initially qualified as a research scientist in biotechnology has had considerable experience in new business development and establishing new start-up companies, particularly in the healthcare industry. In the past two decades he has been involved through Information City Australia with Robert Crompton, in establishing number of successful technology-based businesses including Optias www.optias.com.au, Cell Therapies Pty Ltd, in partnership with the Peter MacCallum Cancer Institute, Genscreen, involved in a range of gene therapies, and Cortical Dynamics, a brain monitoring device with Swinburne University. Ian was a Director of all of these companies.
Robert Crompton has a long career in business growth and development both in Australia and internationally and has been a Director of a number of private and public companies. In partnership with Dr. Ian Smart, he has had a particular focus on the growth and development of Optias over the past decade, and particularly Chronic Healthcare management in Australia’s ageing population. He is also a shareholder and partner of Information City Australia, a high technology incubator which invested in some 80 businesses with $17 million in Government seed funding and $90 million in private co-investment, and Global Access Partners http://www.globalaccesspartners.org/.
Collectively, Perioptias principals have over 50 years' experience in medical and technology commercialisation, as medical professionals in hospitals, as senior executives in government and business, and as research scientists in biotechnology research.
We have addressed a number of opportunities around the world, including
A pharmaceutical company looking to increase its innovative process and engage with the local research market whilst seeking funding from the government.
A materials company with an interest in the aged care sector moving into the space and requiring detailed assessment and research regarding the stem cell and biomanipulation market
Chinese multinationals with a focus on the intersection of Stem Cells, General Practice and Traditional Chinese Medicine;
Laboratories for standardisation procedures and compliance with NATA requirements; and
A multi-site supplier management and coordination of ordering and procurement systems in a Hong Kong hospital
A multinational construction company seeking to strengthen their position in healthcare.
Not quite startups, these businesses are growing and rapidly looking to expand their footprint – either through expanding their geographic reach or seeking additional verticals, like healthcare.
We have a lengthy track record in:
Our team has extensive experience in Private and Multinational Public Company Board representation. In medical and technology commercialisation, Perioptias principals have collaboratively established and managed high technology incubators, raising over $90 million in Joint Venture Capital funding with the creation of more than 80 new businesses and several successful Initial Public Offerings on the Australian Stock-market. Consequently, they have sat on the board or advised leaders in the medical technology field, including stem cells, cancer, anaesthetic and neuromonitoring therapies, devices and services.
Successful commercialisation outcomes include founding:
Periop Partners, a software and services group of businesses at the intersection of health and technology, addressing the problems of access and distribution in healthcare;
Cortical Dynamics, focused on the development of a brain monitoring device to better detect the effect of anaesthetic agents on brain activity, currently in use in hospitals in Australia and internationally;
Bluechiip, which developed an IT-based temperature and identification tracking solution for bio-samples in the health and life-sciences industry, now listed on the Australian Stock Exchange;
Cell Therapies, a joint venture with the Peter MacCallum Cancer Centre, providing clinical trials for new cell based therapies; and
Genscreen, which developed a unique cancer therapy that was licensed to Novogen. (Novogen has now restructure3d with a new MD and returned the IP to Genscreen)